Biomarkers for Primary Sjögren's Syndrome

Genomics, Proteomics and Bioinformatics

Volumn 13, Issue 4, 2015, Pages 219-223

  Chen, Weiqian ^a,b   Cao, Heng ^a   Lin, Jin ^a   Olsen, Nancy ^b   Zheng, Song Guo ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Fms like tyrosine kinase 3 ligand; Myxovirus resistance protein A; Non coding RNAs; Saliva; Sj gren syndrome

Indexed keywords

BIOLOGICAL MARKER; CD135 ANTIGEN; FMS LIKE TYROSINE KINASE 3 LIGAND; INTERFERON; UNCLASSIFIED DRUG; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN;

DISEASE COURSE; GENOMICS; HUMAN; LACRIMAL FLUID; LYMPHOMA; NONHUMAN; PRIMARY SJOEGREN SYNDROME; REVIEW; SALIVA; SJOEGREN SYNDROME; CHEMISTRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; SJOGREN'S SYNDROME;

BIOMARKERS; HUMANS; INTERFERON TYPE I; MEMBRANE PROTEINS; SALIVA; SJOGREN'S SYNDROME; TEARS;

EID: 84944391219     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2015.06.002     Document Type: Review

References (41)

1. Greenspan J.S., Daniels T.E., Talal N., Sylvester R.A. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974, 37:217-229.
2. Fox P.C. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007, 1098:15-21.
3. Mackay F., Groom J.R., Tangye S.G. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2007, 19:406-413.
4. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
5. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
6. Segal B., Bowman S.J., Fox P.C., Vivino F.B., Murukutla N., Brodscholl J., et al. Primary Sjogren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009, 7:46.
7. Kavanaugh A., Tomar R., Reveille J., Solomon D.H., Homburger H.A. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med 2000, 124:71-81.
8. Shiboski S.C., Shiboski C.H., Criswell L., Baer A., Challacombe S., Lanfranchi H., et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012, 64:475-487.
9. Yoshizawa J.M., Schafer C.A., Schafer J.J., Farrell J.J., Paster B.J., Wong D.T. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev 2013, 26:781-791.
10. Henson B.S., Wong D.T. Collection, storage, and processing of saliva samples for downstream molecular applications. Methods Mol Biol 2010, 666:21-30.
11. Xiao H., Zhang L., Zhou H., Lee J.M., Garon E.B., Wong D.T. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics 2012, 11. M111.012112.
12. Hu S., Wang J., Meijer J., Ieong S., Xie Y., Yu T., et al. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum 2007, 56:3588-3600.
13. Fleissig Y., Deutsch O., Reichenberg E., Redlich M., Zaks B., Palmon A., et al. Different proteomic protein patterns in saliva of Sjogren's syndrome patients. Oral Dis 2009, 15:61-68.
14. Deutsch O., Krief G., Konttinen Y.T., Zaks B., Wong D.T., Aframian D.J., et al. Identification of Sjogren's syndrome oral fluid biomarker candidates following high-abundance protein depletion. Rheumatology (Oxford) 2015, 54:884-890.
15. Rawe V.Y., Payne C., Schatten G. Profilin and actin-related proteins regulate microfilament dynamics during early mammalian embryogenesis. Hum Reprod 2006, 21:1143-1153.
16. Botre F., Botre C., Podesta E., Podda M., Invernizzi P. Effect of anti-carbonic anhydrase antibodies on carbonic anhydrases I and II. Clin Chem 2003, 49:1221-1223.
17. Delaleu N., Mydel P., Kwee I., Brun J.G., Jonsson M.V., Jonsson R. High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjogren's syndrome. Arthritis Rheumatol 2015, 67:1084-1095.
18. Nguyen C.Q., Gao J.H., Kim H., Saban D.R., Cornelius J.G., Peck A.B. IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjogren's syndrome-like disease of the nonobese diabetic mouse. J Immunol 2007, 179:382-390.
19. Horikawa K., Takatsu K. Interleukin-5 regulates genes involved in B-cell terminal maturation. Immunology 2006, 118:497-508.
20. Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther 2014, 7:447-456.
21. Tomosugi N., Kitagawa K., Takahashi N., Sugai S., Ishikawa I. Diagnostic potential of tear proteomic patterns in Sjogren's syndrome. J Proteome Res 2005, 4:820-825.
22. Hamm-Alvarez S.F., Janga S.R., Edman M.C., Madrigal S., Shah M., Frousiakis S.E., et al. Tear cathepsin S as a candidate biomarker for Sjogren's syndrome. Arthritis Rheumatol 2014, 66:1872-1881.
23. Maria N.I., Brkic Z., Waris M., van Helden-Meeuwsen C.G., Heezen K., van de Merwe J.P., et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann Rheum Dis 2014, 73:1052-1059.
24. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005, 52:1534-1544.
25. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005, 52:1185-1195.
26. Brkic Z., Versnel M.A. Type I IFN signature in primary Sjogren's syndrome patients. Expert Rev Clin Immunol 2014, 10:457-467.
27. Brkic Z., Maria N.I., van Helden-Meeuwsen C.G., van de Merwe J.P., van Daele P.L., Dalm V.A., et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013, 72:728-735.
28. Emamian E.S., Leon J.M., Lessard C.J., Grandits M., Baechler E.C., Gaffney P.M., et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009, 10:285-296.
29. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni Bocci E., Carubbi F., et al. Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014, 51:75-80.
30. Tobon G.J., Saraux A., Gottenberg J.E., Quartuccio L., Fabris M., Seror R., et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2013, 65:3218-3227.
31. Kramer J.M., Klimatcheva E., Rothstein T.L. CXCL13 is elevated in Sjogren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013, 94:1079-1089.
32. Lee H.T., Shiao Y.M., Wu T.H., Chen W.S., Hsu Y.H., Tsai S.F., et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 2010, 37:45-52.
33. Chua J.H., Armugam A., Jeyaseelan K. MicroRNAs: biogenesis, function and applications. Curr Opin Mol Ther 2009, 11:189-199.
34. Tandon M., Gallo A., Jang S.I., Illei G.G., Alevizos I. Deep sequencing of short RNAs reveals novel microRNAs in minor salivary glands of patients with Sjogren's syndrome. Oral Dis 2012, 18:127-131.
35. Konsta O.D., Thabet Y., Le Dantec C., Brooks W.H., Tzioufas A.G., Pers J.O., et al. The contribution of epigenetics in Sjogren's Syndrome. Front Genet 2014, 5:71.
36. Gallo A., Tandon M., Alevizos I., Illei G.G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012, 7:e30679.
37. Gallo A., Tandon M., Illei G., Alevizos I. Discovery and validation of novel microRNAs in Sjogren's syndrome salivary glands. Clin Exp Rheumatol 2014, 32:761-762.
38. Alevizos I., Alexander S., Turner R.J., Illei G.G. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum 2011, 63:535-544.
39. Pauley K.M., Stewart C.M., Gauna A.E., Dupre L.C., Kuklani R., Chan A.L., et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol 2011, 41:2029-2039.
40. Ice J.A., Adrianto I., Li H., Rasmussen A., Wiley G.B., Stone D.U., et al. Characterization of a Sjögren's syndrome-associated long non-coding RNA at 2P25.1. Ann Rheum Dis 2015, 74(Suppl. 2):794.
41. Thabet Y., Le Dantec C., Ghedira I., Devauchelle V., Cornec D., Pers J.O., et al. Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells. J Autoimmun 2013, 41:175-181.